SGLT2 inhibitors for heart failure with preserved ejection fraction will be the No. 10 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
Promising observational data suggest it’s time for a prospective study of this therapy in heart failure patients with reduced ejection fraction and low cardiac output who are receiving IV therapies.
Encouraging findings from this sham-controlled study of the Carillon device for transvenous mitral annuloplasty in functional mitral regurgitation pique interest in the large ongoing CARILLON trial.
The data is showing some positive results, and the nursing team continues to examine if group education for heart failure patients might improve outcomes. There are many factors.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Looking for benchmarks for heart failure or arrhythmia care? Check out some of our latest volume and outcome data in these areas via this dynamic infographic.
Quality improvement successes don’t just happen but instead result from core principles and best practices. A QI leader shares secrets behind recent quality successes in STEMI care, heart failure and more.
The veteran heart failure cardiologist shares his goals as president, why he thinks his subspecialty is so dynamic these days and what he most wishes other specialists recognized about heart failure care.
Heart failure and stepdown units of the Sydell and Arnold Miller Family Heart & Vascular Institute have been testing electrocardiogram technology.
The national PI of the ROADMAP trial shares his passion for VADs, current research projects that excite him and why he made a mid-career move to Cleveland Clinic.
Our experts share eight trends and developments that excite them most in mechanical circulatory support and beyond.